Q2 FY2026 · ended Jun 30, 2026 · Revenue $4,988, +55.0% YoY · Filed Aug 19, 2026
BioAdaptives Inc. (BDPT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $4,988 and net income of $150,090. Free cash flow was -$44,385.
Revenue
$4,988
+55.0% vs year-ago quarter
Net income
$150,090
+195.0% vs year-ago quarter
Operating cash flow
$-44,385
+60.0% vs year-ago quarter
Free cash flow
$-44,385
+65.6% vs year-ago quarter
EPS
$0.00
+100.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
196.93M
+1879.4% vs year-ago quarter
Net cash
—
Operating margin
-3557.0%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BDPT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Las Vegas, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1575142
- Former names
- APEX 8 Inc. (until Aug 19, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $4,988 | $5,514 | $10,427 | $4,632 | $3,219 |
| Operating income | -$197,176 | -$198,218 | -$248,117 | -$265,689 | -$279,219 |
| Net income | $150,090 | -$111,086 | -$823,346 | -$379,502 | -$157,914 |
| Diluted EPS | $0.00 | -$0.01 | -$0.07 | -$0.04 | -$0.02 |
| Operating cash flow | -$44,385 | -$84,839 | -$155,828 | -$151,309 | -$110,982 |
| Free cash flow | -$44,385 | — | -$155,828 | -$151,309 | -$128,982 |
| Total assets | $78,767 | $135,949 | $225,901 | $124,360 | $272,515 |
| Total liabilities | $1.8M | $2.3M | $2.4M | $1.6M | $1.4M |
| Stockholders' equity | -$1.8M | -$2.1M | -$2.1M | -$1.5M | -$1.1M |
| Cash and investments | $29,221 | $73,606 | $158,445 | $59,273 | $210,582 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Nov 4, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Aug 19, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Apr 14, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
All 176 BioAdaptives Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.